INTELLIA THERAPEUTICS, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2023-05-01: Disclosure Pay versus Performance Table; Period 2022-01-01..2022-12-31; Value Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Act and Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid to our principal executive officer ( “ PEO ” ) and the other named executive officers ( “ NEO….
- 2023-05-01: Disclosure Adjustment To PEO Compensation Footnote; Period 2022-01-01..2022-12-31; Value (1) The amounts reported represent the “compensation actually paid” to our PEO, computed in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to our PEO in the applicable year. In accordance with Item 402(v) of Regulation S-K, the f….
- 2023-05-01: Disclosure Adjustment To Compensation; Qualifiers AdjToComp: SctValueOfEquityAwards; ExecutiveCategory: Peo; Period 2022-01-01..2022-12-31; Value -$9.04M.
- 2023-05-01: Disclosure Adjustment To Compensation; Qualifiers AdjToComp: EquityAwardAdjustments; ExecutiveCategory: Peo; Period 2022-01-01..2022-12-31; Value -$15.13M.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2023-05-01 DEF 14A | Pay versus Performance Table | 2022-01-01..2022-12-31 | Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Act and Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid to our principal executive officer ( “ PEO ” ) and the other named executive officers ( “ NEO… | |
| 2023-05-01 DEF 14A | Adjustment To PEO Compensation Footnote | 2022-01-01..2022-12-31 | (1) The amounts reported represent the “compensation actually paid” to our PEO, computed in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to our PEO in the applicable year. In accordance with Item 402(v) of Regulation S-K, the f… | |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: SctValueOfEquityAwards; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$9.04M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustments; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$15.13M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: SctValueOfEquityAwards; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$8.69M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustments; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $36.69M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: SctValueOfEquityAwards; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | -$2.72M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustments; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $18.37M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfEquityAwardsGrantedDuringTheYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $3.78M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwards; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$12.38M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$6.52M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfEquityAwardsGrantedDuringTheYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $18.66M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwards; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $10.77M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $7.26M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfEquityAwardsGrantedDuringTheYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $11.82M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwards; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $5.17M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $1.38M |
| 2023-05-01 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2022-01-01..2022-12-31 | (2) The amounts reported represent the average “compensation actually paid” to the NEOs other than our PEO as a group, computed in accordance with Item 402(v) of Regulation S-K. The amounts do not reflect the actual average amount of compensation earned by or paid to such NEOs as a group in the appl… | |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: AverageSctValueOfEquityAwards; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$3.23M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: AverageEquityAwardAdjustments; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$5.56M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: AverageSctValueOfEquityAwards; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$6.35M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: AverageEquityAwardAdjustments; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $15.46M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: AverageSctValueOfEquityAwards; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | -$1.18M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: AverageEquityAwardAdjustments; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $6.89M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfEquityAwardsGrantedDuringTheYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $1.15M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwards; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$4.61M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$2.10M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfEquityAwardsGrantedDuringTheYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $10.13M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwards; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $3.66M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $1.67M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfEquityAwardsGrantedDuringTheYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $5.17M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwards; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $1.53M |
| 2023-05-01 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $189.13K |
| 2023-05-01 DEF 14A | Named Executive Officers Footnote | 2022-01-01..2022-12-31 | (6) Non-PEO NEOs for 2022 include Mr. Goddard, Mr. Basta, Mr. Hicks, Dr. Lebwohl and Dr. Sepp-Lorenzino. (7) Non-PEO NEOs for 2021 include Mr. Goddard, Mr. Basta, Dr. Lebwohl and Dr. Sepp-Lorenzino. (8) Non-PEO NEOs for 2020 include Mr. Goddard, Dr. Lebwohl, Dr. Sepp-Lorenzino and Dr. Schiermeier, o… | |
| 2023-05-01 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2022-01-01..2022-12-31 | Compensation Actually Paid and Total Shareholder Return As shown in the graph below, compensation actually paid to our PEO and the average compensation actually paid to the Company’s other NEOs is generally aligned with the Company’s TSR over the three-year period from December 31, 2019 to December … | |
| 2023-05-01 DEF 14A | Compensation Actually Paid Vs Net Income | 2022-01-01..2022-12-31 | Compensation Actually Paid and Net Income (Loss) As a clinical-stage company, we did not have any net income during the periods presented and we have not historically considered net income (loss) in evaluating or determining executive compensation. Our net loss has increased over the three-year peri… |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |